What new data related to the use of TNFIs and the use of IL-6 inhibitors do we have as it relates to drug persistence and safety profiles?

What new data related to the use of TNFIs and the use of IL-6 inhibitors do we have as it relates to drug persistence and safety profiles?

What new data related to the use of TNFIs and the use of IL-6 inhibitors do we have as it relates to drug persistence and safety profiles?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Ernest Choy, MD, FRCP

Ernest Choy, MD, FRCP

Head of Rheumatology and Translational Research
Institute of Infection and Immunity
Director of Arthritis Research UK CREATE Centre and
Welsh Arthritis Research Network (WARN) Cardiff University School of Medicine
Cardiff, United Kingdom